What SEC filings does Clover Health Investments, Corp. submit to the SEC?

Clover Health Investments, Corp. (CLOV) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CLOV?

A Form 4 for CLOV discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Clover Health Investments, Corp.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CLOV?

The 10-K is Clover Health Investments, Corp.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CLOV SEC filings directly on EDGAR?

You can view all historical Clover Health Investments, Corp. filings on the SEC EDGAR company page for CLOV. Each filing card on this page links directly to the original SEC document.

How often does Clover Health Investments, Corp. file with the SEC?

Clover Health Investments, Corp. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CLOV shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CLOV SEC Filing News — Clover Health Investments, Corp.

Latest SEC filings for Clover Health Investments, Corp. (CLOV) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

Sector: Healthcare Industry: Healthcare Plans Market Cap: $2.4B CIK: 1801170

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CLOV currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

CLOV Filing Activity Snapshot 2026-09-17 — 2026-10-15

Insider Transactions (Form 4)

0 buys vs 5 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.34M

Toy Andrew (Director, Chief Executive Officer) · 2026-10-02

318,806 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 7 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 7 filings in this group are Form 4s for Clover Health Investments, Corp.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 7 insider filings shown, the breakdown is 5 open-market sale and 2 compensation award. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×5: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Open-market sale Insider Selling 2026-10-07

CLOV insider Reynoso Jamie L. (CEO, Medicare Advantage) sold 2,006 shares (~$9.3K)

Reynoso Jamie L., listed as CEO, Medicare Advantage at CLOVER HEALTH INVESTMENTS, CORP. /DE, reported an open-market sale of 2,006 CLOV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,006	$4.63	$9.3K

Filing: Form 4 (Insider Transaction) Insider: Reynoso Jamie L. (CEO, Medicare Advantage) Shares: 2,006 Est. Value: $9.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-05

CLOV insider Reynoso Jamie L. (CEO, Medicare Advantage) sold 8,750 shares (~$38.7K)

Reynoso Jamie L., listed as CEO, Medicare Advantage at CLOVER HEALTH INVESTMENTS, CORP. /DE, reported an open-market sale of 8,750 CLOV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	8,750	$4.42	$38.7K

Filing: Form 4 (Insider Transaction) Insider: Reynoso Jamie L. (CEO, Medicare Advantage) Shares: 8,750 Est. Value: $38.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CLOV insider Form 4 filed for equity award, exercise, or tax withholding

Miller Brian James (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	12,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Miller Brian James (Director) Shares: 12,481

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CLOV insider Form 4 filed for equity award, exercise, or tax withholding

Torricelli Robert G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	12,481	—	—

Filing: Form 4 (Insider Transaction) Insider: Torricelli Robert G (Director) Shares: 12,481

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-02

CLOV insider Toy Andrew (Director, Chief Executive Officer) sold 318,806 shares (~$1.34M)

Toy Andrew, listed as Director, Chief Executive Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE, reported an open-market sale of 318,806 CLOV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	318,806	$4.19	$1.34M

Filing: Form 4 (Insider Transaction) Insider: Toy Andrew (Director, Chief Executive Officer) Shares: 318,806 Est. Value: $1.34M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-18

CLOV insider Reynoso Jamie L. (CEO, Medicare Advantage) sold 1,921 shares (~$8.8K)

Reynoso Jamie L., listed as CEO, Medicare Advantage at CLOVER HEALTH INVESTMENTS, CORP. /DE, reported an open-market sale of 1,921 CLOV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,921	$4.56	$8.8K

Filing: Form 4 (Insider Transaction) Insider: Reynoso Jamie L. (CEO, Medicare Advantage) Shares: 1,921 Est. Value: $8.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-17

CLOV insider OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 3,170 shares (~$14.7K)

OLDAKOWSKI JOSEPH FRANK, listed as VP OF FINANCE AND CONTROLLER at CLOVER HEALTH INVESTMENTS, CORP. /DE, reported an open-market sale of 3,170 CLOV shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,170	$4.64	$14.7K

Filing: Form 4 (Insider Transaction) Insider: OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) Shares: 3,170 Est. Value: $14.7K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 10 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Clover Health Investments, Corp. has 10 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.